<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01032499</url>
  </required_header>
  <id_info>
    <org_study_id>E01-GOU-INH-01-09</org_study_id>
    <nct_id>NCT01032499</nct_id>
  </id_info>
  <brief_title>Open and Comparative Study to Measure Tolerability and Efficacy of Taro Elixir</brief_title>
  <acronym>E01GOU-INH0109</acronym>
  <official_title>Multicenter Clinical Study,Phase III, Prospective, Randomized, Open and Comparative to Measure Tolerability and Efficacy of Taro Elixir on the Evolution Treatment of Acne Vulgaris II and III Degree or of Furunculosis Compared With Oxytetracycline</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Goulart S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Goulart S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To measure the efficacy of Taro Elixir compare with Oxytetracycline in the treatment of boils
      or acne.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">October 2010</completion_date>
  <primary_completion_date type="Anticipated">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure the efficacy in the treatment of boils or acne vulgaris II and III degree with taro elixir compared with Oxytetracycline.</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure the tolerability in the treatment evolution of boils or acne vulgaris II and III with taro elixir compare with Oxytetracycline.</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Acne Vulgaris II or III Degree</condition>
  <condition>Boils</condition>
  <arm_group>
    <arm_group_label>oxytetracycline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Taro Elixir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Taken orally one tablespoon (15 mL) of Taro Elixir 3 times daily for breakfast, lunch and dinner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxytetracycline, taro elixir</intervention_name>
    <description>comparison of treatment efficacy between oxytetracycline and taro elixir</description>
    <arm_group_label>oxytetracycline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taro Elixir</intervention_name>
    <description>Taken orally one tablespoon (15 mL) of Taro Elixir 3 times daily for breakfast, lunch and dinner.</description>
    <arm_group_label>Taro Elixir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both of gender patient, older than 14 years;

          -  Patient with boils or acne vulgaris II or III degree;

          -  The score must be at least than 4, for 2 or more question of VAS (visual analog
             scale);

          -  Patient that have been used an effective contraceptive method in the last 3 months,
             including sexual abstinence and that keep using that method during the study until a
             month after;

          -  Patient that have been accepted to participate of the study and signed the Informed
             Consent or in case of younger than 18 years, the responsable must read and sign the
             Informed Consent.

          -  Patient that have been accepted to meet all the visits stipulated at the protocol,
             whenever the investigator request in .

        Exclusion Criteria:

          -  Patient of female gender that has been pregnant, breastfeeding or that has not been
             use a safe contraceptive method (oral contraceptives or barrier methods). Sexual
             abstinence will be accept if the investigator think that it is relevant.

          -  Patient that has been use antiandrogens (cyproterone, finasteride, flutamide,
             tamoxifen, spironolactone);

          -  Patient with acne I or IV degree;

          -  Patient that has been receive some treatment for acne as antibiotics, corticosteroid
             or any medicine that can maybe interfere in the study results: a month for systemic
             treatment or two weeks for topic treatment, before inclusion or during the study;

          -  Patient that received treatment with oral retinoids within 6 months before the
             inclusion and during the study;

          -  Patient that had a known decompensated diabetes history;

          -  Patient with immunodeficiency and liver, renal, cardiac, digestive, metabolic,
             endocrinological, hematological, neurological or psychiatric disorders, evaluated
             through anamnesis by the investigator, tha can maybe interfere on the study
             evaluation. Even the patient with facial dermatoses such as psoriasis, acne rosacea,
             allergic dermatitis, skin infections caused by fungi, bacteria and viruses;

          -  Patient with alcoholism history, illicit drugs use, psychological ou emotional
             problems that can maybe void the Informed Consent or limit the capacity of the patient
             follow the protocol requirements ;

          -  Patient hypersensitive to any one of the medicine components;

          -  Patient that have been used any drug under search, 3 months before the visit number
             one.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Machado</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculdade de Medicina do ABC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea Gerbase</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alergoclínica - Centro de Alergia e dermatologia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Denise Steiner</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlínica Mogi das Cruzes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jussara Marin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alergoclínica - Centro de alergia e dermatologia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlos Machado</last_name>
    <phone>+55 11 4993-5400</phone>
    <email>dermatologia@fmabc.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Selma Squassoni</last_name>
    <phone>+55 11 49935459</phone>
    <email>selma_denis@yahoo.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Policlínica de Mogi das Cruzes</name>
      <address>
        <city>Mogi das Cruzes</city>
        <state>São Paulo</state>
        <zip>08780070</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Denise Steiner</last_name>
      <phone>+55 11 4728-5383</phone>
      <email>steiner@uol.com.br</email>
    </contact>
    <investigator>
      <last_name>Denise Steiner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Faculdade de Medicina do ABC</name>
      <address>
        <city>Santo André</city>
        <state>São Paulo</state>
        <zip>09060650</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlos Machado</last_name>
      <phone>+55 11 4993-5400</phone>
      <email>dermatologia@fmabc.br</email>
    </contact>
    <contact_backup>
      <last_name>Selma Squassoni</last_name>
      <phone>+55 11 49935459</phone>
      <email>selma_denis@yahoo.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Carlos Machado</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alergoclínica - Centro de alergia e dermatologia</name>
      <address>
        <city>São Paulo</city>
        <zip>03066030</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jussara Marin</last_name>
      <phone>+55 11 2942-1833</phone>
      <email>jmarin@alergoclinica.com.br</email>
    </contact>
    <investigator>
      <last_name>Jussara Marin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alergoclínica - Centro de alergia e dermatologia</name>
      <address>
        <city>São Paulo</city>
        <zip>04505000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Gerbase</last_name>
      <phone>+55 11 5682-8711</phone>
      <email>andrea.gerbase@alergoclinica.com.br</email>
    </contact>
    <investigator>
      <last_name>Andrea Gerbase</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2009</study_first_submitted>
  <study_first_submitted_qc>December 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2009</study_first_posted>
  <last_update_submitted>March 18, 2010</last_update_submitted>
  <last_update_submitted_qc>March 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>Voltaire Gominho de Oliveira</name_title>
    <organization>Laboratorios Goulart S.A.</organization>
  </responsible_party>
  <keyword>Acne Vulgaris</keyword>
  <keyword>Boil</keyword>
  <keyword>Taro Elixir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytetracycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

